Darren M. Harvey

Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation

Michael J. Thomenius, Jennifer Totman, Darren M. Harvey et al. · PLoS ONE · 2018 · 55 citations · Full text

Life Sciences, Molecular Biology, Oncology +13

Synthesis, structure–property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y12 receptor

Peter Bach, Jonas Boström, Kay Brickmann et al. · European Journal of Medicinal Chemistry · 2013 · 42 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

A general approach to the galanthamine ring system

Philip J. Parsons, Mark Charles, Darren M. Harvey et al. · Tetrahedron Letters · 2001 · 39 citations · Full text

Natural Sciences, Chemistry, Medicinal Chemistry +5

Discovery of a First-in-Class Inhibitor of the Histone Methyltransferase SETD2 Suitable for Preclinical Studies

John W. Lampe, Joshua S. Alford, P. Ann Boriak-Sjodin et al. · ACS Medicinal Chemistry Letters · 2021 · 37 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Tandem reactions of anions: A short and efficient route to ±anatoxin-a

Philip J. Parsons, Nicholas P. Camp, J. M. Underwood et al. · Tetrahedron · 1996 · 31 citations

Natural Sciences, Chemical Engineering, Chemistry +12